Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate | Zendy

Kathleen Chiotos | Zendy; Jeffrey S. Gerber | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate

Author(s) -

Kathleen Chiotos,

Jeffrey S. Gerber

Publication year - 2021

Publication title -

jac-antimicrobial resistance

Language(s) - English

Resource type - Journals

ISSN - 2632-1823

DOI - 10.1093/jacamr/dlab153

Subject(s) - procalcitonin , community acquired pneumonia , pneumonia , intensive care medicine , medicine , antibiotic resistance , antibiotics , bacterial pneumonia , pediatrics , immunology , biology , microbiology and biotechnology , sepsis

Although the overwhelming majority of community-acquired pneumonia (CAP) in children is caused by viral infections, treatment of CAP is among the most common indications for antibiotic use in children. This is largely driven by the imprecision of clinical diagnostic tools to differentiate viral from bacterial pneumonia and highlights the need for improved approaches to optimizing management of CAP in children. In this issue of JAC-Antimicrobial Resistance , we present a PRO/CON debate that discusses the clinical utility of procalcitonin in children with CAP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research